GlassScriptPhysician profile
Daisy M Behman
NPI 1780694166
$6,839.72
in general payments reported to CMS, 2019-2025
56 companies · $784 in 2025
The $784 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $852 · 2021: $1,208 · 2022: $1,244 · 2023: $937 · 2024: $1,008 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.00 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $961.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $879.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $608.11 | 2020-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $424.63 | 2019-2022 | |
| Abbott Laboratories | $394.86 | 2021-2025 | Freestyle Libre |
| Dexcom, INC. | $362.63 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $282.42 | 2022-2025 | Ubrelvy |
| Medtronic, INC. | $254.51 | 2021-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $216.66 | 2022-2025 | Ingrezza, Ongentys |
| Sanofi-Aventis U.S. LLC | $204.81 | 2019-2025 | |
| Insulet Corporation | $149.33 | 2023-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.48 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $146.84 | 2019-2021 | |
| Ucb, INC. | $118.90 | 2019-2025 | Nayzilam, Briviact |
| Medtronic Minimed, INC. | $106.78 | 2019-2020 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $103.49 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $102.75 | 2019-2021 | |
| Amryt Pharma Holdings LTD | $80.58 | 2023 | Myalept |
| Amneal Pharmaceuticals LLC | $78.46 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $75.45 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $72.82 | 2019-2021 | |
| Lundbeck LLC | $70.16 | 2022-2024 | Vyepti |
| Mannkind Corporation | $69.99 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $66.05 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $56.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.98 | 2019 | |
| Greenwich Biosciences, INC. | $47.86 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $46.28 | 2022-2023 | Firdapse |
| Embecta Corp. | $44.70 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Pfizer INC. | $37.33 | 2019-2024 | |
| Celgene Corporation | $35.94 | 2024-2025 | Zeposia |
| Cequr Corporation | $34.64 | 2022-2024 | Cequr Simplicity |
| Argenx US, INC. | $34.37 | 2022-2024 | Vyvgart Hytrulo |
| Ibsa Pharma INC. | $32.72 | 2024-2025 | Licart, Tirosint, Flector |
| Kyowa Kirin, INC. | $32.06 | 2019-2023 | Crysvita |
| Recordati_rare_diseases_inc. | $31.78 | 2024 | Signifor Lar, Isturisa |
| Chiesi USA, INC. | $30.86 | 2024 | Myalept |
| Scilex Pharmaceuticals INC. | $28.33 | 2022-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $28.27 | 2020-2025 | Austedo Xr |
| Lifescan, INC. | $27.95 | 2019-2020 | |
| Amgen INC. | $25.69 | 2019-2024 | Repatha |
| Biogen, INC. | $21.67 | 2020 | |
| Madrigal Pharmaceuticals | $20.23 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $19.59 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $19.00 | 2023 | Crysvita |
| Supernus Pharmaceuticals, INC. | $15.84 | 2019 | |
| Daiichi Sankyo INC. | $15.74 | 2023 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Currax Pharmaceuticals LLC | $14.96 | 2025 | Onzetra Xsail |
| Vertical Pharmaceuticals, LLC | $14.92 | 2019 | |
| Aquestive Therapeutics, INC. | $14.51 | 2022 | |
| Sk Life Science, INC. | $14.17 | 2022 | |
| Avion Pharmaceuticals | $13.21 | 2023 | Dhivy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2019 | |
| Alfasigma USA, INC. | $13.01 | 2021 | |
| Eisai INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Behman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.